CSL (OTCMKTS:CSLLY) Downgraded to Strong Sell Rating by Zacks Research

Zacks Research downgraded shares of CSL (OTCMKTS:CSLLY) from a hold rating to a strong sell rating in a research note issued to investors on Monday morning,Zacks.com reports.

CSLLY has been the subject of several other reports. Royal Bank Of Canada cut shares of CSL from a “moderate buy” rating to a “hold” rating in a research note on Wednesday, February 11th. Citigroup lowered shares of CSL from a “strong-buy” rating to a “hold” rating in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold”.

CSL Price Performance

Shares of CSLLY stock opened at $17.75 on Monday. CSL has a 12 month low of $17.64 and a 12 month high of $44.86. The company has a current ratio of 2.57, a quick ratio of 1.15 and a debt-to-equity ratio of 0.51. The stock has a 50 day moving average of $24.02 and a 200-day moving average of $46.65.

About CSL

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.